Meeting
2020 Genitourinary Cancers Symposium
A systematic review and network meta-analysis of FDA approved treatment options in men with nonmetastatic, castration-resistant prostate cancer (M0CRPC).
Authors
Irbaz Bin Riaz
Mayo Clinic, Rochester, MN
Irbaz Bin Riaz , Noureen Asghar , Daenielle K. Lang , Yuan Yao , Anum Riaz , Abdulaali Almutairi , Zhen Wang , Ivo Abraham , M. Hassan Murad , Manish Kohli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 335)
Abstract #
335
Poster Bd #
M19
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).
First Author: Tomasz M. Beer
Poster
2021 Genitourinary Cancers Symposium
Retrospective cohort analysis of real-world clinical outcomes in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) treated with novel androgen receptor pathway inhibitors (ARPI).
First Author: Richard Gagnon
Poster
2020 Genitourinary Cancers Symposium
Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.
First Author: Amanda Elizabeth Hird
Poster
2019 ASCO Annual Meeting
Outcomes of men with recurrent M0 prostate cancer who defer androgen deprivation therapy until metastasis.
First Author: Catherine Handy Marshall